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Abstract
BACKGROUND/OBJECTIVES—Osteoporosis affects approximately 2 million men in the
U.S., however, few osteoporosis clinical studies include men. The objective of this study was to
evaluate the evidence for efficacy of treatment options to reduce osteoporotic fracture risk for men.
DESIGN—Systematic review and meta-analysis.
DATA SOURCES—PubMed, Embase, and Cochrane Library databases.
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STUDY SELECTION—Randomized clinical trials that evaluated the efficacy of a treatment for
osteoporosis or low bone mineral density for adult male participants and reported fracture
outcomes.
DATA EXTRACTION—Information extracted included participant sociodemographic
characteristics; number of male participants; treatment/intervention(s) and comparator evaluated;
study duration; and fracture outcome(s). Risk of bias of individual studies was assessed using
measures recommended by the Cochrane Collaboration.
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RESULTS—Twenty-four articles reporting results for 22 different studies (including 4868 male
participants) met strict inclusion criteria. Fixed-effects meta-analyses using the Mantel-Haenszel
method demonstrated significantly reduced risk of vertebral fractures with alendronate (RR 0.328,
95% CI 0.155–0.692) and risedronate (RR 0.428, 95% CI 0.245–0.746), but not with calcitonin
(RR 0.272, 95% CI 0.046–1.608) or denosumab (RR 0.256, 95% CI 0.029–2.238). For
bisphosphonates as a treatment category, meta-analyses demonstrated significantly reduced risk of
vertebral fractures (RR 0.368, 95% CI 0.252–0.537) and nonvertebral fractures (RR 0.604, 95% CI
0.404–0.904). The meta-analysis finding that bisphosphonates significantly reduce nonvertebral
fracture risk was not robust to sensitivity analysis.
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CONCLUSION—Bisphosphonates reduce the risk of vertebral and possibly nonvertebral
fractures for men with osteoporosis. Further studies are needed to evaluate the efficacy of
bisphosphonates for reducing nonvertebral fracture risk and the efficacy of non-bisphosphonates
for reducing vertebral and nonvertebral fracture risk for men with osteoporosis.
Keywords
osteoporosis; fractures; systematic review; meta-analysis

INTRODUCTION
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Osteoporosis affects 2 million men in the United States,1 and approximately 1 in 5 white
men will sustain an osteoporotic fracture in his lifetime.2 Men are estimated to incur 29% of
all osteoporotic fractures and account for 25% of total osteoporosis-related costs.3
Furthermore, men have higher mortality rates after hip fracture than women, with nearly 1 in
3 men over the age of 65 years who incur a hip fracture dying within the following year.4
The morbidity, mortality, and costs secondary to osteoporotic fractures in the U.S. are
considerable and likely to increase in upcoming years with the aging of the population.2–9
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Despite the prevalence of osteoporosis among older men and potential severity of its health
consequences, osteoporosis in men is significantly understudied compared with women;
most osteoporosis clinical studies to date have not included male participants.10 FDAapproved osteoporosis treatment options for men include alendronate, risedronate,
zoledronic acid, teriparatide, and denosumab, and osteoporosis treatment for men is
recommended by several organizations.11,12 We performed a systematic review and metaanalysis of the evidence for fracture risk reduction for different osteoporosis treatment
options for men.

METHODS
Data sources and search strategies
We developed broad literature search strategies for PubMed, Embase, and Cochrane Library
databases to locate randomized clinical trials reporting on the efficacy of osteoporosis
treatment options. We performed initial literature searches on 8/15/14 for Embase; 8/28/14
for PubMed; and 11/28/14 for the Cochrane Library. The PubMed search was updated on
3/18/16. The database search strategies are available upon request. We identified additional
studies by reviewing the reference lists of topical review papers and studies meeting our
inclusion criteria as well as studies identified by experts.

Author Manuscript

Study selection
We applied inclusion and exclusion criteria to literature identified with the search strategies
to select studies of interest. We included studies that evaluated the efficacy of a treatment for
adults with osteoporosis or low bone mineral density (BMD); were randomized clinical
trials; reported separate data for male participants or had male participants only; and
reported fracture outcomes, with provision of either numbers or percentages of men in each
study group who sustained incident fractures. We included studies published in any
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language, and had no restrictions on study participant comorbidities. We excluded studies in
which not all participants were identified as having osteoporosis or low BMD (T-score ≤–1).
We evaluated studies for inclusion in two stages – we first reviewed titles and abstracts,
followed by full-text review of studies that were identified as potentially relevant after title/
abstract review.
Data extraction

Author Manuscript

Information extracted from eligible studies included study participant sociodemographic
characteristics; number of male participants; study location; treatment/intervention(s)
evaluated; comparator for evaluated treatment/intervention; duration of study/follow-up
period for fracture outcomes; fracture outcome(s) evaluated; and results reported for fracture
outcomes in intervention and comparator groups. For fracture outcomes, we extracted data
on numbers of participants in the intervention and comparator groups who sustained incident
fractures.
Data analysis
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We qualitatively described included study characteristics and study quality. For study quality
assessment, we used measures recommended by the Cochrane Collaboration for assessing
risk of bias for individual studies, including criteria to evaluate risk of selection bias,
performance bias, detection bias, attrition bias, and reporting bias.13 We also performed
fixed-effects meta-analyses using the Mantel-Haenszel method14 to calculate summary
relative risk of fracture estimates for each individual treatment option for which there were
at least two studies with similar comparators and fracture outcomes assessed; and for
bisphosphonates when considered as a treatment category. Between-study heterogeneity in
each performed meta-analysis was assessed with I2 values. For studies that reported fracture
outcomes for multiple follow-up time periods, we used the fracture outcomes reported for
the longest follow-up time period when performing meta-analyses. For meta-analyses that
included 3 or more studies, we also performed influence (sensitivity) analysis in which we
excluded individual studies one at a time to assess whether meta-analysis findings were
robust to exclusion of individual studies. We used Stata version 11.0 (StataCorp, College
Station, TX) to perform these analyses.

RESULTS
Literature search and study selection
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The literature searches identified a total of 6475 records (citations) for review; 2673 of these
records were excluded because they were duplicates (same citation found in different
databases), leaving 3802 unique records for review. Twenty-four of these records reporting
results for 22 different studies met inclusion criteria.15–38 Figure 1 shows a flow diagram of
the literature search and study selection.
Study characteristics
Supplementary Table S1 shows included study characteristics. Included studies were
published between 1998 and 2013, number of male study participants ranged from 23 to
1199, and study duration ranged from 1 to 3 years. Approximately half of the included
J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 4

Author Manuscript

studies evaluated the efficacy of bisphosphonate medications, with more studies assessing
alendronate or zoledronic acid than other bisphosphonates. Most included studies compared
a treatment option to placebo and/or calcium and vitamin D only; very few had active
comparators. A majority of studies included only men with primary osteoporosis and/or
hypogonadal osteoporosis, and did not include men with other causes of secondary
osteoporosis. Many of the included studies had largely white study participant populations.
Commonly assessed osteoporosis fracture outcomes included all vertebral fractures
(morphometric – detected by x-rays, including asymptomatic as well as symptomatic
vertebral fractures); clinical vertebral fractures (meaning symptomatic vertebral fractures
only); nonvertebral fractures; and clinical fractures (clinically symptomatic fractures at any
site). Vertebral fractures were the most commonly assessed fracture outcomes, followed by
nonvertebral fractures and clinical fractures.
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Only one included study, a study by Boonen et al. evaluating zoledronic acid therapy,
reported having sufficient statistical power for fracture outcomes for men, for the outcome of
morphometric vertebral fractures.36 Only 4 studies reported relative risk, odds ratio, or
hazard ratio of fracture for men in the intervention groups compared to the comparator
groups;17,18,29,30,35,36 of these, 3 studies evaluating alendronate, risedronate, and zoledronic
acid reported a statistically significant reduction in risk of fracture for men receiving the
evaluated intervention/treatment compared to the comparator; all for the outcome of
vertebral fractures,18,29,30,36 and only one study evaluating risedronate for the outcome of
nonvertebral fractures.30 Only two included studies performed head-to-head comparisons of
drugs that are FDA-approved for men – one study that compared teriparatide to
alendronate,33 and another study that compared zoledronic acid to alendronate;38 neither of
these studies reported relative risk for fracture outcomes. A majority of studies reported
pharmaceutical company funding.15,16,19,21–25,27,28,31,33–36,38
Study quality and potential sources of bias
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Supplementary Table S2 shows findings of our assessment of included study quality using
criteria recommended by the Cochrane Collaboration for assessing risk of bias for individual
studies. In general, studies did not sufficiently describe their methods of random sequence
generation, allocation concealment, and whether all pre-specified outcomes in the study
protocol were reported on in the pre-specified way to permit judgment of “low risk” or “high
risk” of bias for these domains. Thus, most studies were assessed as “unclear risk” of bias
for the categories of selection bias and reporting bias. A majority of studies reported
blinding of fracture outcome assessment, and thus were assessed as low risk for detection
bias. Studies were mixed with respect to domains of reporting of blinding of participants and
personnel, as well as incomplete outcome data, which fall within categories of performance
bias and attrition bias, respectively. No included study was assessed as low risk of bias for
all evaluated domains, and thus no study received a summary assessment of low risk of bias.
A slight majority of studies received a summary assessment of high risk of bias (due to at
least one bias domain being assessed as high risk of bias), with the remainder of the studies
receiving a summary assessment of unclear risk of bias.

J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 5

Meta-analyses

Author Manuscript

Sufficiently similar studies were available for separate meta-analyses for the outcome of
vertebral fractures for alendronate, calcitonin, denosumab, and risedronate; for the outcome
of nonvertebral fractures for alendronate; and for the outcome of clinical fractures with
zoledronic acid. When considering bisphosphonates as a treatment category, sufficiently
similar studies were available for outcomes of vertebral fractures, clinical vertebral fractures,
nonvertebral fractures, and clinical fractures. Meta-analysis results are shown in Table 1.
Forest plots for the meta-analyses are shown in Supplementary Figures S1–S10.
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For individual treatment options, the meta-analyses findings demonstrated significantly
reduced risk of vertebral fractures with alendronate (RR 0.328, 95% CI 0.155–0.692) and
risedronate (RR 0.428, 95% CI 0.245–0.746), but not with calcitonin (RR 0.272, 95% CI
0.046–1.608) or denosumab (RR 0.256, 9 5% CI 0.029–2.238). The meta-analyses findings
for individual treatment options did not demonstrate significantly reduced risk of
nonvertebral fractures with alendronate (RR 0.751, 95% CI 0.352–1.602) or clinical
fractures with zoledronic acid (RR 0.742, 95% CI 0.436–1.263). When considering
bisphosphonates as a treatment category, meta-analyses findings demonstrated significantly
reduced risk of vertebral fractures (RR 0.368, 95% CI 0.252–0.537) and nonvertebral
fractures (RR 0.604, 95% CI 0.404–0.904), but not clinical vertebral fractures (RR 0.398,
95% CI 0.105–1.506) or clinical fractures (RR 0.791, 95% CI 0.500–1.253). Between-study
heterogeneity in each performed meta-analysis was low as demonstrated by low I2 values.
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The meta-analysis finding that bisphosphonates significantly reduce risk of vertebral
fractures was robust to influence analysis, with summary estimates of relative risk of
vertebral fractures with bisphosphonate therapy ranging from 0.353–0.391 with removal of
individual studies, and the lower limit of the 95% CI ranging from 0.215–0.265 and the
upper limit of the 95% CI ranging from 0.518–0.594 with removal of individual studies.
However, the finding that bisphosphonates significantly reduce risk of nonvertebral fractures
was sensitive to removal of the study by Ringe et al. in 2009 that evaluated risedronate
therapy for men30 – when this study was removed from the analysis, the summary estimate
for relative risk of nonvertebral fractures with bisphosphonate therapy was 0.715, with a
95% CI of 0.382–1.337. The meta-analysis findings of nonsignificant reduction in the
relative risk of clinical vertebral fractures or clinical fractures with bisphosphonates were
robust to influence analysis, with results remaining nonsignificant with removal of any
individual study in either analysis.

DISCUSSION
Author Manuscript

Relatively few randomized clinical trials have been performed to date to assess efficacy of
osteoporosis treatment options for reducing fracture risk for men. Our meta-analysis findings
for individual treatment options demonstrated that alendronate and risedronate significantly
reduce risk of vertebral fracture for men; however, our meta-analyses for individual
treatment options did not demonstrate evidence of statistically significant reduction in
vertebral fracture risk for men with calcitonin or denosumab, nonvertebral fracture risk for
men with alendronate, or clinical fracture risk for men with zoledronic acid. Our metaanalyses findings for bisphosphonates when considered as a treatment category
J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.
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demonstrated significantly reduced risk of vertebral fractures and nonvertebral fractures, but
not clinical vertebral fractures or clinical fractures. Our results for significant reduction in
the relative risk of nonvertebral fractures with bisphosphonate therapy were sensitive to the
removal of the study by Ringe et al. in 2009 that demonstrated significantly reduced risk of
nonvertebral fracture for men with risedronate therapy.30 There were insufficient data to
perform meta-analyses for the efficacy of calcitriol, monoflourophosphate, parathyroid
hormone, strontium ranealate, or teriparatide for reducing fracture risk for men.
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Our meta-analyses were limited by the number of similar studies assessing each medication,
with only 2 studies included in each separate meta-analysis of individual medications that
we performed, and 3–6 studies included in each separate meta-analysis we performed for
different fracture outcomes when evaluating bisphosphonates as a treatment category.
Additionally, many of the included studies in our meta-analyses had small sample sizes.
Furthermore, although one included study demonstrated significant reduction in
morphometric vertebral fracture risk with zoledronic acid treatment,36 there were not two
studies similar enough to perform a meta-analysis for the efficacy of zoledronic acid
treatment on fracture outcomes for men. Moreover, our systematic review and meta-analysis
findings are limited by the caveat that all studies included in our systematic review and
meta-analysis were assessed as having unclear or high risk of bias. However, despite these
limitations our findings suggest that in the absence of additional evidence bisphosphonates
should preferentially be used as first-line osteoporosis treatment for men given evidence for
their efficacy in reducing vertebral fracture risk, and possibly nonvertebral fracture risk as
well. Our findings for the evidence of bisphosphonate efficacy to reduce fracture risk for
men apply to individuals who have osteoporosis or low BMD by DXA criteria, or who have
had a prior osteoporotic fracture, as the studies included in this systematic review and metaanalysis included participants who met these criteria. Further studies are needed to evaluate
the efficacy of osteoporosis treatment for men with risk factors for fracture who are not
known to have osteoporosis or low BMD by DXA criteria or prior osteoporotic fracture.

Author Manuscript

Our study highlights the need for additional high-quality, sufficiently powered for fracture
outcomes randomized clinical studies of osteoporosis treatment efficacy for men,
particularly for nonvertebral fracture outcomes, and for non-bisphosphonate treatment
options such as denosumab or teriparatide. Our findings also highlight the lack of active
comparator randomized clinical trials of osteoporosis treatment for men; additional studies
of osteoporosis treatment for men with active comparators would help clarify the relative
efficacy of different treatment options for reducing fracture risk. Additionally, our findings
reveal the need for greater diversity of participants in clinical trials of osteoporosis treatment
for men; most included studies in our systematic review had largely white study participant
populations. Finally, no study included in our systematic review had a duration greater than
3 years, and thus the efficacy of longer osteoporosis treatment durations to reduce fracture
risk for men is unknown – additional studies with longer durations would be helpful to
evaluate the impact of osteoporosis treatment for longer durations than 3 years on fracture
risk for men, similar to longer duration osteoporosis treatment studies that have
demonstrated fracture risk reduction benefit for women.39
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Our study has several notable strengths. Our study is the most comprehensive systematic
review and meta-analysis of randomized clinical trials of osteoporosis treatment efficacy for
reducing fracture risk for men to date. A prior systematic review and meta-analysis on the
topic of osteoporosis treatment efficacy for men by Schwarz et al. published in 2011
included only five studies that reported fracture outcomes, and concluded that the evidence
for osteoporosis treatment for men to reduce fracture risk was inconclusive.40 Our
systematic review and meta-analysis, which included 22 randomized clinical studies of
osteoporosis treatment for men that reported fracture outcomes, finds evidence for the
efficacy of bisphosphonate medications for reducing risk of vertebral fractures and possibly
nonvertebral fractures for men. Another strength of our study was the assessment of risk of
bias of individual randomized clinical trials included in our systematic review using criteria
recommended by the Cochrane Collaboration.
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In conclusion, our findings support the use of bisphosphonates to reduce vertebral and
possibly nonvertebral fracture risk for men with osteoporosis. Further studies are needed to
evaluate the efficacy of bisphosphonates for reducing nonvertebral fracture risk for men, and
to evaluate the efficacy of non-bisphosphonate treatment options such as denosumab or
teriparatide to reduce vertebral and nonvertebral fracture risk for men.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
Author Manuscript

Funding Sources: Dr. Nayak was supported by grant R01AR060809 from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases and a Swedish Foundation Philanthropy at Work award; Dr. Greenspan was
supported by NIH grant P30AG024827 from the National Institute on Aging.
Dr. Greenspan is on the scientific advisory board for Merck & Co.
Sponsor’s Role: The sponsors had no role in the design, methods, data collection, analysis, or preparation of the
paper.
Additional Contributions: The authors thank Eric S. Orwoll, MD and Arthur C. Santora II, MD, PhD, for providing
requested data.

Appendix
Conflict of Interest Checklist:

Author Manuscript

Elements of
Financial/Personal
Conflicts

SN

Yes

SLG

No

Yes

No

Employment or Affiliation

X

X

Grants/Funds

X

X

Honoraria

X

X

J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 8

Author Manuscript

Elements of
Financial/Personal
Conflicts

SN

Yes

SLG

No

Yes

No

Speaker Forum

X

X

Consultant

X

X

Stocks

X

X

Royalties

X

X

Expert Testimony

X

Board Member

X

Patents

X

X

Personal Relationship

X

X

X
X

Author Manuscript

For “yes”, provide a brief explanation: Dr. Greenspan is on the scientific advisory board for
Merck & Co.

REFERENCES

Author Manuscript
Author Manuscript

1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in
the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner
Res. 2014 Nov; 29(11):2520–2526. [PubMed: 24771492]
2. U.S. Department of Health and Human Services. Rockville, MD: U.S. Department of Health and
Human Services, Office of the Surgeon General; 2004. Bone Health and Osteoporosis: A Report of
the Surgeon General.
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosisrelated fractures in the United States, 2005–2025. J Bone Miner Res. 2007 Mar; 22(3):465–475.
[PubMed: 17144789]
4. Bass E, French DD, Bradham DD, et al. Risk-adjusted mortality rates of elderly veterans with hip
fractures. Ann Epidemiol. 2007 Jul; 17(7):514–519. [PubMed: 17420142]
5. Brenneman SK, Yurgin N, Fan Y. Cost and management of males with closed fractures. Osteoporos
Int. 2013 Mar; 24(3):825–833. [PubMed: 22776864]
6. MacDermid JC, Roth JH, Richards RS. Pain and disability reported in the year following a distal
radius fracture: a cohort study. BMC Musculoskelet Disord. 2003 Oct 31.4:24. [PubMed:
14588078]
7. Orsini LS, Rousculp MD, Long SR, et al. Health care utilization and expenditures in the United
States: a study of osteoporosis-related fractures. Osteoporos Int. 2005 Apr; 16(4):359–371.
[PubMed: 15340799]
8. Ortiz-Alonso FJ, Vidan-Astiz M, Alonso-Armesto M, et al. The pattern of recovery of ambulation
after hip fracture differs with age in elderly patients. J Gerontol A Biol Sci Med Sci. 2012 Jun;
67(6):690–697. [PubMed: 22219518]
9. Venmans A, Klazen CA, Lohle PN, et al. Natural history of pain in patients with conservatively
treated osteoporotic vertebral compression fractures: results from VERTOS II. AJNR Am J
Neuroradiol. 2012 Mar; 33(3):519–521. [PubMed: 22116114]
10. Haney EM, Bliziotes MM. Male osteoporosis: new insights in an understudied disease. Curr Opin
Rheumatol. 2008 Jul; 20(4):423–428. [PubMed: 18525355]
11. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of
Osteoporosis. Osteoporos Int. 2014 Oct; 25(10):2359–2381. [PubMed: 25182228]
12. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical
practice guideline. J Clin Endocrinol Metab. 2012 Jun; 97(6):1802–1822. [PubMed: 22675062]

J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 9

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of
bias in randomised trials. BMJ. 2011 Oct.343:d5928. [PubMed: 22008217]
14. Egger, M., Smith, GD., Altman, DG. Systematic reviews in health care : meta-analysis in context.
2nd. Egger, MatthiasSmith, George Davey, Altman, Douglas G., editors. London: BMJ Books;
2001. (2003 [printing])
15. Miller PD, Schnitzer T, Emkey R, et al. Weekly oral alendronic Acid in male osteoporosis. Clin
Drug Investig. 2004; 24(6):333–341.
16. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl
J Med. 2000 Aug 31; 343(9):604–610. [PubMed: 10979796]
17. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men:
results of a 2-year prospective study. J Clin Endocrinol Metab. 2001 Nov; 86(11):5252–5255.
[PubMed: 11701687]
18. Ringe JD, Dorst A, Faber H, et al. Alendronate treatment of established primary osteoporosis in
men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004 Mar; 24(2):
110–113. [PubMed: 13680141]
19. Shimon I, Eshed V, Doolman R, et al. Alendronate for osteoporosis in men with androgen-repleted
hypogonadism. Osteoporos Int. 2005 Dec; 16(12):1591–1596. [PubMed: 16362147]
20. Toth E, Csupor E, Meszaros S, et al. The effect of intranasal salmon calcitonin therapy on bone
mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.
Bone. 2005 Jan; 36(1):47–51. [PubMed: 15664001]
21. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men
with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res.
2002 Mar; 17(3):521–527. [PubMed: 11874243]
22. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone
turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind,
double placebo study. J Clin Endocrinol Metab. 2001 Sep; 86(9):4098–4103. [PubMed: 11549632]
23. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with
denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture
intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014 Jul;
99(7):2599–2607. [PubMed: 24646104]
24. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the
effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol
Metab. 2012 Sep; 97(9):3161–3169. [PubMed: 22723310]
25. Orwoll ES, Binkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men
with low bone density. Bone. 2010 Apr; 46(4):970–976. [PubMed: 20060082]
26. Ringe JD, Dorst A, Kipshoven C, et al. Avoidance of vertebral fractures in men with idiopathic
osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
Osteoporos Int. 1998; 8(1):47–52. [PubMed: 9692077]
27. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic
osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab.
2000 Sep; 85(9):3069–3076. [PubMed: 10999788]
28. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis:
results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009
Apr; 24(4):719–725. [PubMed: 19049326]
29. Ringe JD, Faber H, Farahmand P, et al. Efficacy of risedronate in men with primary and secondary
osteoporosis: results of a 1-year study. Rheumatol Int. 2006 Mar; 26(5):427–431. [PubMed:
16001181]
30. Ringe JD, Farahmand P, Faber H, et al. Sustained efficacy of risedronate in men with primary and
secondary osteoporosis: results of a 2-year study. Rheumatol Int. 2009 Jan; 29(3):311–315.
[PubMed: 18762944]
31. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the
treatment of osteoporosis in men. J Clin Endocrinol Metab. 2013 Feb; 98(2):592–601. [PubMed:
23341486]

J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 10

Author Manuscript
Author Manuscript

32. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men
with osteoporosis. Arzneimittelforschung. 2010; 60(5):267–272. [PubMed: 20533764]
33. Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoidinduced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009 Dec;
20(12):2095–2104. [PubMed: 19350340]
34. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–
34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003 Jan; 18(1):9–17.
[PubMed: 12510800]
35. Boonen S, Orwoll E, Magaziner J, et al. Once-yearly zoledronic acid in older men compared with
women with recent hip fracture. J Am Geriatr Soc. 2011 Nov; 59(11):2084–2090. [PubMed:
22091563]
36. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with
osteoporosis. N Engl J Med. 2012 Nov; 367(18):1714–1723. [PubMed: 23113482]
37. Kachnic LA, Pugh SL, Tai P, et al. RTOG 0518: randomized phase III trial to evaluate zoledronic
acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate
Cancer Prostatic Dis. 2013 Dec; 16(4):382–386. [PubMed: 24080992]
38. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. Infusion of
zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male
osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res.
2010 Oct; 25(10):2239–2250. [PubMed: 20499357]
39. Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med. 2012 May 31; 366(22):2051–2053. [PubMed:
22571169]
40. Schwarz P, Jorgensen NR, Mosekilde L, et al. The evidence for efficacy of osteoporosis treatment
in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and
anabolic treatment in men. J Osteoporos. 2011; 2011:259818. [PubMed: 21776371]

Author Manuscript
Author Manuscript
J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Figure 1.

Author Manuscript

Flow diagram of literature search and study selection

J Am Geriatr Soc. Author manuscript; available in PMC 2018 March 01.

Nayak and Greenspan

Page 12

Table 1

Author Manuscript

Meta-Analysis Results

Author Manuscript

a

Treatment

Included studies

Summary estimates of fracture relative risk (RR)
from meta-analysisa (95%CI; I2 valueb)

Alendronate

Orwoll 200016,c & Ringe 200418

Vertebral fractures: 0.328 (0.155–0.692; I2=29.4%);
Nonvertebral fractures: 0.751 (0.352–1.602); I2=0.0%)

Calcitonin

Toth 200520 & Trovas 200221

Vertebral fractures: 0.272 (0.046–1.608; I2=0.0%)

Denosumab

Nakamura 201323 & Orwoll 201224

Vertebral fractures: 0.256 (0.029–2.238; I2=0.0%)

200928

200930

Vertebral fractures: 0.428 (0.245–0.746; I2=27.4%)

Risedronate

Boonen

Zoledronic acid

Boonen 201135 & Boonen 201236

Clinical fractures: 0.742 (0.436–1.263; I2=0.0%)

Any bisphosphonate
(alendronate,
ibandronate,
risedronate, or
zoledronic acid)

Boonen 200928, Boonen 201236, Orwoll 200016,
Orwoll 201025, Ringe 200418, Ringe 200930
(vertebral fractures meta-analysis);
Boonen 201236, Orwoll 200016, Orwoll 201025
(clinical vertebral fractures meta-analysis)d;
Boonen 201236, Orwoll 200016, Ringe 200418, Ringe
200930 (nonvertebral fractures meta-analysis);
Boonen 200928, Boonen 201135, Boonen 201236,
Orwoll 201025 (clinical fractures meta-analysis)

Vertebral fractures: 0.368 (0.252–0.537; I2=0.0%);
Vertebral fractures (clinical only): 0.398 (0.105–1.506;
I2=0.0%);
Nonvertebral fractures: 0.604 (0.404–0.904; I2=0.0%);
Clinical fractures: 0.791 (0.500–1.253; I2=0.0%)

& Ringe

Fixed-effects meta-analysis using Mantel-Haenszel method

b

Percentage of variation across studies attributable to heterogeneity

c

For Orwoll 2000 study, vertebral fracture results reported when using quantitative assessment method were used for meta-analysis

d

Shimon 2005 study excluded from analysis due to no fracture events in intervention or comparator groups
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